tetano
Editor, Senior Moderator
Front Public Health
. 2024 Sep 18:12:1419886.
doi: 10.3389/fpubh.2024.1419886. eCollection 2024. Tracking temporal variations of fatality and symptomology correlated with COVID-19 dominant variants and vaccine effectiveness in the United States
Shao Lin[SUP] 1 2 [/SUP], Han Liu[SUP] 3 [/SUP], Quan Qi[SUP] 4 [/SUP], Ian Trees[SUP] 5 [/SUP], Donghong Gao[SUP] 2 [/SUP], Samantha Friedman[SUP] 6 [/SUP], Xiaobo Romeiko Xue[SUP] 1 [/SUP], David Lawrence[SUP] 1 7 [/SUP]
Affiliations
Introduction: We described how COVID-19 fatality and symptoms varied by dominant variant and vaccination in the US.
Methods: Using the Restricted Access Dataset from the US CDC (1/1/2020-10/20/2022), we conducted a cross-sectional study assessing differences in COVID-19 deaths, severity indicators (hospitalization, ICU, pneumonia, abnormal X-ray, acute respiratory distress syndrome, mechanical ventilation) and 12 mild symptoms by dominant variant/vaccination periods using logistic regression after controlling for confounders.
Results: We found the highest fatality during the dominant periods of Wild (4.6%) and Delta (3.4%). Most severe symptoms appeared when Delta was dominant (Rate range: 2.0-9.4%). Omicron was associated with higher mild symptoms than other variants. Vaccination showed consistent protection against death and severe symptoms for most variants (Risk Ratio range: 0.41-0.93). Boosters, especially the second, provided additional protection, reducing severe symptoms by over 50%.
Discussion: This dataset may serve as a useful tool to monitor temporospatial changes of fatality and symptom for case management and surveillance.
Keywords: COVID-19; booster; deaths; dominant viral variants; mild symptoms; severe symptoms; vaccination.
. 2024 Sep 18:12:1419886.
doi: 10.3389/fpubh.2024.1419886. eCollection 2024. Tracking temporal variations of fatality and symptomology correlated with COVID-19 dominant variants and vaccine effectiveness in the United States
Shao Lin[SUP] 1 2 [/SUP], Han Liu[SUP] 3 [/SUP], Quan Qi[SUP] 4 [/SUP], Ian Trees[SUP] 5 [/SUP], Donghong Gao[SUP] 2 [/SUP], Samantha Friedman[SUP] 6 [/SUP], Xiaobo Romeiko Xue[SUP] 1 [/SUP], David Lawrence[SUP] 1 7 [/SUP]
Affiliations
- PMID: 39360263
- PMCID: PMC11445176
- DOI: 10.3389/fpubh.2024.1419886
Introduction: We described how COVID-19 fatality and symptoms varied by dominant variant and vaccination in the US.
Methods: Using the Restricted Access Dataset from the US CDC (1/1/2020-10/20/2022), we conducted a cross-sectional study assessing differences in COVID-19 deaths, severity indicators (hospitalization, ICU, pneumonia, abnormal X-ray, acute respiratory distress syndrome, mechanical ventilation) and 12 mild symptoms by dominant variant/vaccination periods using logistic regression after controlling for confounders.
Results: We found the highest fatality during the dominant periods of Wild (4.6%) and Delta (3.4%). Most severe symptoms appeared when Delta was dominant (Rate range: 2.0-9.4%). Omicron was associated with higher mild symptoms than other variants. Vaccination showed consistent protection against death and severe symptoms for most variants (Risk Ratio range: 0.41-0.93). Boosters, especially the second, provided additional protection, reducing severe symptoms by over 50%.
Discussion: This dataset may serve as a useful tool to monitor temporospatial changes of fatality and symptom for case management and surveillance.
Keywords: COVID-19; booster; deaths; dominant viral variants; mild symptoms; severe symptoms; vaccination.